Novartis

NovartisNovartis provides innovative healthcare solutions that address the evolving needs of patients and societies. Headquartered in Basel, Switzerland, Novartis offers a diversified portfolio to best meet these needs: innovative medicines, eye care and cost-saving generic pharmaceuticals. Novartis is the only global company with leading positions in these areas. In 2015, the Group achieved net sales of USD 49.4 billion, while R&D throughout the Group amounted to approximately USD 8.9 billion (USD 8.7 billion excluding impairment and amortization charges). Novartis Group companies employ approximately 118,000 full-time-equivalent associates. Novartis products are available in more than 180 countries around the world.

www.novartis.com

Novartis RSS Channel

Filters
List of articles in category Novartis
Title Published Date
Three scientists to receive Novartis prizes for immunology 18 June 2013
Novartis receives EU approval for Ilaris® in patients suffering acute gouty arthritis attacks 03 March 2013
Novartis drug Votubia® approved as first medication to treat patients with non-cancerous kidney tumors associated with TSC 04 November 2012
Novartis receives European Commission approval for once-daily Seebri® Breezhaler® as maintenance COPD treatment 01 October 2012
Novartis data at ERS shows efficacy of once-daily COPD portfolio versus comparators 03 September 2012
Afinitor® approved by European Commission to treat patients with the most common form of advanced breast cancer 31 July 2012
CHMP recommends Novartis drug Afinitor® for EU approval 22 June 2012
Novartis drug Signifor® approved in the EU as the first medication to treat patients with Cushing's disease 27 April 2012
Novartis QVA149 Phase III COPD studies meet primary endpoints 03 April 2012
European Commission approves new label for Novartis drug Glivec® 28 February 2012
Novartis to revise product information in the European Union for high blood pressure drug Rasilez® following assessment by CHMP 17 February 2012
Novartis drug Signifor® recommended by CHMP for EU approval 19 January 2012
Novartis Foundation symposium looks at impact of Information and Communication Technology 02 December 2011
Novartis gains European Commission approval for Rasitrio® 28 November 2011
Novartis associates participate in first company-wide health and well-being initiative 21 September 2011
Novartis drug Afinitor® gains EU approval to treat patients with advanced pancreatic neuroendocrine tumors 05 September 2011
Novartis drug Afinitor® recommended by CHMP 25 July 2011
Novartis delivers strong financial results and four major approvals 19 July 2011
Novartis drug Afinitor® met primary endpoint of Phase III study in women with advanced breast cancer 06 July 2011
Novartis drug Votubia® recommended by CHMP for approval in the EU 24 June 2011